文献速递消化、代谢与肾脏急症儿科与产科急症

虚拟现实对成人急诊镰状细胞病血管闭塞危象患者吗啡节省用量的影响

Effect of use of virtual reality on morphine-sparing in patients with sickle cell disease for main management of vaso-occlusive crises in an adult emergency department.
PubMed 文献 · Eur J Emerg Med · 2025-10-23
一句话结论在成人急诊镰状细胞病血管闭塞危象患者中,加用虚拟现实未减少急诊吗啡总剂量,但患者满意度高。

该研究为法国成人急诊开展的前瞻性前后对照研究,纳入97例镰状细胞病血管闭塞危象急性疼痛患者,非干预阶段50例按标准方案处理,干预阶段47例在常规治疗基础上可加用虚拟现实。主要终点为急诊期间吗啡总剂量,虚拟现实组中位剂量30.7 mg(IQR 19.7-45.7),对照组37.7 mg(IQR 24.7-53.3),两组中位差值-7 mg(95%CI -18.6至4.6)。虚拟现实组18.2%(8/44)报告不良反应,以头晕(50%)、恶心(25%)、头痛(25%)为主;83.3%(35/42)表示愿意再次使用。结论认为虚拟现实未减少急诊吗啡总剂量,但似能有效整合入多模式疼痛管理且患者满意度高。

要点

  • 在成人急诊镰状细胞病血管闭塞危象患者中,加用虚拟现实组吗啡中位总剂量30.7 mg(IQR 19.7-45.7)vs 对照组37.7 mg(IQR 24.7-53.3),中位差值-7 mg(95%CI -18.6至4.6),未减少吗啡用量。
  • 虚拟现实组18.2%(8/44)报告不良反应,主要为头晕(50%)、恶心(25%)、头痛(25%)。
  • 虚拟现实组83.3%(35/42)表示愿意再次使用该方法,提示接受度高。
  • 研究为前瞻性前后对照设计,共纳入97例,非干预阶段50例、干预阶段47例。
  • 作者结论认为虚拟现实未减少急诊吗啡总剂量,但似可有效整合入多模式疼痛管理。

适用人群与场景

  • 法国成人急诊中镰状细胞病血管闭塞危象所致急性疼痛的患者。

处置流程与药物剂量

  • 非干预阶段患者按标准方案处理,不使用虚拟现实。
  • 干预阶段患者在常规治疗基础上可接受虚拟现实 sessions。

研究设计与关键结果

  • 研究类型为前瞻性前后对照研究,纳入97例患者,非干预阶段50例、干预阶段47例。
  • 主要终点急诊吗啡总剂量:虚拟现实组中位30.7 mg(IQR 19.7-45.7)vs 对照组37.7 mg(IQR 24.7-53.3),中位差值-7 mg(95%CI -18.6至4.6)。
  • 虚拟现实组18.2%(8/44)报告不良反应,包括头晕(50%)、恶心(25%)、头痛(25%)。
  • 虚拟现实组83.3%(35/42)表示愿意再次使用该方法。

证据类型、等级与局限

  • 证据类型为前瞻性前后对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在该前瞻性研究中,虚拟现实未减少急诊镰状细胞病血管闭塞危象急性疼痛患者的吗啡总剂量,但虚拟现实似可有效整合入多模式疼痛管理,且患者满意度高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND IMPORTANCE: Vaso-occlusive crisis is the main reason for emergency department (ED) visits for patients with sickle cell disease. Therapeutic management involves multimodal analgesia, which often comprises the administration of morphine. Recently, the use of virtual reality (VR) has garnered growing interest as a nonpharmacological approach for pain modulation.

OBJECTIVE: The objective of this study was to assess the impact of integrating VR on the reduction of the total dose of morphine administered during vaso-occlusive crisis.

SETTINGS AND PARTICIPANTS: This was a prospective before-and-after study conducted in a French adult ED on patients with sickle cell disease and acute pain from vaso-occlusive crisis.

INTERVENTION OR EXPOSURE: During the first period, patients were managed according to the standard protocol, with no use of VR. During the second period, patients were able to benefit from VR sessions in addition to the usual care.

OUTCOME MEASURES AND ANALYSIS: The primary outcome was the total dose of morphine administered in the ED. Secondary objectives were to evaluate the feasibility, tolerance, acceptability, and effectiveness of VR in pain management, measured using a numeric rating scale.

MAIN RESULTS: A total of 97 patients were included in the study, 50 during the noninterventional phase and 47 during the interventional phase. The median morphine dose was 30.7 mg [interquartile range (IQR), 19.7-45.7] in the VR group and 37.7 mg (IQR, 24.7-53.3) in the control group. The median difference between the two groups was -7 mg [95% confidence interval (CI), (-18.6 to 4.6)]. In the VR group, 18.2% of patients (8 out of 44 responders) reported side effects, which included primarily dizziness (50%), followed by nausea (25%) and headaches (25%). Additionally, 83.3% (35 out of 42 responders) of patients expressed the desire to use this method again.

CONCLUSION: In this prospective study, the use of VR did not reduce the total morphine dose administered in the ED for patients with acute pain and vaso-occlusive crisis. However, the use of VR appeared to be effectively integrated into multimodal pain management, with a high level of patient satisfaction.

来源:Eur J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Dubreucq Guerif E, Agut S, Rousseau A, et al. Effect of use of virtual reality on morphine-sparing in patients with sickle cell disease for main management of vaso-occlusive crises in an adult emergency department. Eur J Emerg Med. 2025. PMID: 41143717. doi:10.1097/MEJ.0000000000001282

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。